HELP YOUR ELIGIBLE PATIENTS SAVE ON BEPREVE*
With the Bausch + Lomb Access Program, eligible* commercially insured patients may pay as little as $25 co-pay. Eligible* uninsured patients or not covered patients may pay as little as $70 co-pay.
- Patients who receive a physical co-pay card in office can activate online at blsavings.com, on the phone by calling 1-866-693-4880, or by texting BLSAVINGS to 24109.†
- Once the card has been downloaded or activated, patients can take it to Walgreens or a participating independent pharmacy to pick up their prescription.
- Discount pricing is also available for eligible uninsured patients.*
Indications and Usage
BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.
Important Safety Information
- BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients.
- To minimize contaminating the dropper tip and solution, advise the patient not to touch the eyelids or surrounding areas with the dropper tip of the bottle and to keep the bottle tightly closed when not in use.
- BEPREVE should not be used to treat contact lens-related irritation.
- Patient should remove contact lenses prior to instillation of BEPREVE, because benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes after BEPREVE administration.
- The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for Prescribing Information for BEPREVE.
Indications and Usage
BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with allergic conjunctivitis.
Important Safety Information
- BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients.
- To minimize contaminating the dropper tip and solution, advise the patient not to touch the eyelids or surrounding areas with the dropper tip of the bottle and to keep the bottle tightly closed when not in use.
- BEPREVE should not be used to treat contact lens-related irritation.
- Patient should remove contact lenses prior to instillation of BEPREVE, because benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes after BEPREVE administration.
- The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for Prescribing Information for BEPREVE.